Literature DB >> 31125758

Neuroendocrine abnormalities associated with untreated first episode patients with major depressive disorder and bipolar disorder.

GuoHua Feng1, ChuanYuan Kang2, Jing Yuan1, Yan Zhang1, YuJun Wei1, Li Xu1, Fang Zhou1, Xinxin Fan1, JianZhong Yang3.   

Abstract

There are few studies that explore simultaneously the relationship of neuroendocrine hormones of the HPA, HPT and HPG axes with major depressive disorder (MDD) and bipolar disorder (BD). The aim of this study is to examine the relationship of neuroendocrine pathways with affective disorders by comparing the differences in measures of neuroendocrine function between untreated first episode patients with MDD and BD. A cohort of 679 MDD and 83 BD patients was recruited. Thyroid stimulating hormone (TSH), triiodothyronine (T3), free triiodothyronine (FT3), thyroxine (T4), free thyroxin (FT4), cortisol (COR), adrenocorticotropic hormone (ACTH), estradiol (E2) and testosterone (T) were determined by chemiluminesent immunoassay for all patients. COR and ACTH were both significantly higher in the MDD group than those in BD group. The incidences of high secretion of ACTH and COR, and low thyroid hormone secretion were significantly greater in MDD patients than in BD patients. Decreased T secretion was more common in BD than MDD patients. ACTH was significantly positively correlated with HAMD total score and negatively correlated with FT3 in MDD patients. FT3 and FT4 levels were significantly negatively correlated with the somatoform factor score of HAMD in MDD patients. Untreated first episode patients with MDD have a hyperactivity of the HPA axis, lower HPT compared with BD patients. BD patients had reduced testosterone secretion. These findings indicate that ACTH, FT3 and FT4 could be used as markers for severity and symptoms of untreated first episode patients with MDD.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Bipolar disorder; Major depressive disorder; Neuroendocrine

Mesh:

Substances:

Year:  2019        PMID: 31125758     DOI: 10.1016/j.psyneuen.2019.05.013

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  6 in total

1.  Peripheral biomarkers to predict the diagnosis of bipolar disorder from major depressive disorder in adolescents.

Authors:  Xiaohui Wu; Zhiang Niu; Yuncheng Zhu; Yifan Shi; Hong Qiu; Wenjie Gu; Hongmei Liu; Jie Zhao; Lu Yang; Yun Wang; Tiebang Liu; Yong Xia; Yan Yang; Jun Chen; Yiru Fang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-08-25       Impact factor: 5.760

2.  Biochemical and Endocrine Parameters for the Discrimination and Calibration of Bipolar Disorder or Major Depressive Disorder.

Authors:  Yuncheng Zhu; Haifeng Ji; Zhiang Niu; Hongmei Liu; Xiaohui Wu; Lu Yang; Zuowei Wang; Jun Chen; Yiru Fang
Journal:  Front Psychiatry       Date:  2022-06-20       Impact factor: 5.435

3.  Serum Vitamin D Concentrations Are Associated With Depressive Symptoms in Men: The Sixth Korea National Health and Nutrition Examination Survey 2014.

Authors:  Sang Jin Rhee; Hyunju Lee; Yong Min Ahn
Journal:  Front Psychiatry       Date:  2020-07-30       Impact factor: 4.157

4.  Comparison of blood lipid profile/thyroid function markers between unipolar and bipolar depressed patients and in depressed patients with anhedonia or suicidal thoughts.

Authors:  Meilei Su; Enze Li; Chong Tang; Yongzhi Zhao; Ruqing Liu; Keming Gao
Journal:  Mol Med       Date:  2019-11-20       Impact factor: 6.354

5.  Chronic Stress in Bipolar Disorders Across the Different Clinical States: Roles of HPA Axis and Personality.

Authors:  Manxue Zhang; Shengnan Zhao; Yuexin Chen; Xu Zhang; Yuwei Li; Peiwei Xu; Yi Huang; Xueli Sun
Journal:  Neuropsychiatr Dis Treat       Date:  2022-08-12       Impact factor: 2.989

6.  LTBP1 plays a potential bridge between depressive disorder and glioblastoma.

Authors:  Xiaojun Fu; Pei Zhang; Hongwang Song; Chenxing Wu; Shengzhen Li; Shouwei Li; Changxiang Yan
Journal:  J Transl Med       Date:  2020-10-15       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.